Bortezomib (Velcade)
A proteasome inhibitor used in multiple myeloma and mantle cell lymphoma, given by subcutaneous or IV injection in combination regimens.
What is Bortezomib?
What it targets
The proteasome, a cellular structure that breaks down misfolded proteins — blocking it causes toxic protein buildup that triggers death in myeloma cells.
Who it may help
Adult patients with multiple myeloma, and selected patients with mantle cell lymphoma.
Why testing matters
Blood counts, kidney and liver function, and a check for peripheral neuropathy symptoms are needed before starting and during treatment.
Which cancers can Bortezomib treat?
Bortezomib is approved for multiple myeloma and mantle cell lymphoma. It may also be studied in other blood cancer settings in clinical trials.
| Multiple myeloma | Used in first-line therapy, relapse, transplant-based plans, and selected consolidation or maintenance-type approaches. Proteasome inhibitor combinations remain a major standard of care in myeloma as of NCCN guidelines version 2026. |
| Mantle cell lymphoma | Used in selected patients including those unsuitable for stem cell transplant; EMA label includes a combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for previously untreated patients. |
| Other blood cancers (clinical trial) | May be studied or considered off-label in selected hematologic malignancies. Use outside approved indications depends entirely on specialist judgment and trial availability. |
Who may be eligible for Bortezomib?
Eligibility is determined by your hemato-oncologist based on diagnosis, disease stage, organ function, and prior treatment history.
- Confirmed diagnosis of multiple myeloma requiring systemic treatment.
- Confirmed diagnosis of mantle cell lymphoma in appropriate clinical setting.
- Adequate kidney function — dose adjustment not usually needed for renal impairment.
- Liver function tests within acceptable range, as bortezomib is metabolised hepatically.
- No uncontrolled active serious infection at the time of treatment start.
- Baseline peripheral neuropathy assessment — existing severe neuropathy may limit suitability.
- Platelet count and white blood cell count reviewed — significant blood count suppression may require dose delay or adjustment.
- Viral screening including hepatitis B completed, especially if rituximab or other immunosuppressives are co-administered.
How does Bortezomib work?
- Blocking the 26S proteasome
- Why myeloma cells are especially vulnerable
- Triggering cancer cell death
- Combination effect
Tests needed before starting Bortezomib
Your oncologist will order baseline tests before starting treatment. These guide eligibility, dosing, and monitoring.
| Complete Blood Count (CBC) | Checks hemoglobin, white cell count, and platelets. Repeated regularly throughout treatment to monitor blood count suppression. |
| Kidney function tests | Urea, creatinine, and eGFR assessment. Bortezomib does not require renal dose adjustment but kidney function guides overall treatment planning. |
| Liver function tests | ALT, AST, alkaline phosphatase, and bilirubin. Required because bortezomib is primarily metabolised by the liver. |
| Calcium, albumin, LDH | Disease-related blood markers important in multiple myeloma staging and response assessment. |
| Serum protein electrophoresis and free light chains | M-protein and serum free light chain testing in multiple myeloma. Establishes the disease marker to be tracked during treatment for response assessment. |
| Bone marrow biopsy and FISH / cytogenetics | Required in multiple myeloma when not already done. Cytogenetic risk stratification guides treatment planning and combinations. |
| Imaging (PET-CT, whole-body MRI, or low-dose CT) | Baseline disease extent assessment in myeloma or lymphoma, depending on disease type and protocol. |
| Hepatitis B screening | Mandatory before immunosuppressive combination therapy. Positive hepatitis B carriers require antiviral management before and during treatment. |
| Baseline nerve assessment | Peripheral neuropathy grading at baseline. Pre-existing neuropathy may require dose adjustment or alternative scheduling. |
How is Bortezomib given?
Bortezomib is given by injection, either under the skin or into a vein. Subcutaneous injection is now the preferred route in most centers because it reduces the risk of peripheral neuropathy compared with intravenous use.
| Route — subcutaneous (preferred) | Injected under the skin of the thigh or abdomen. Preferred route in most current protocols as it reduces peripheral neuropathy risk compared to IV. |
| Route — intravenous (IV) | Injected directly into a vein as a bolus injection. Used in some protocols or when subcutaneous access is not suitable. |
| Dose and schedule | Dose is calculated by body surface area. Typical schedules include once or twice weekly administration during defined treatment cycles with rest periods between cycles. |
| Administration setting | Given at a hospital day care unit or oncology infusion center by trained nursing staff. Not self-administered at home. |
| Missed dose | Contact your oncology team immediately if you miss a scheduled injection. Do not double up. Your team will advise whether to reschedule or skip and continue with the next planned dose. |
| Treatment duration | Duration depends on the regimen, treatment goal, response, and tolerability. Induction therapy may run for 4 to 8 cycles. Maintenance-type approaches vary by protocol. Your oncologist sets the duration and reviews it at each assessment. |
Clinical evidence and benefits of Bortezomib
Bortezomib has established clinical evidence across multiple myeloma treatment lines and is a guideline-recommended proteasome inhibitor in international oncology practice.
| Established myeloma backbone | Bortezomib-based combinations remain standard of care in newly diagnosed and relapsed multiple myeloma per NCCN version 2026 and IMWG recommendations. |
| Response in newly diagnosed myeloma | VRd (bortezomib, lenalidomide, dexamethasone) and similar triplet regimens have demonstrated deep responses in transplant-eligible and transplant-ineligible newly diagnosed myeloma patients in large randomised studies. |
| Rapid disease control | Bortezomib can produce measurable responses within one to two cycles in many patients. This is particularly important in myeloma complicated by kidney injury, where rapid light chain reduction can help reverse organ damage. |
| Efficacy in high-risk cytogenetics | Bortezomib-based regimens retain activity in some cytogenetically high-risk myeloma subgroups, though not uniformly. Combination with daratumumab or second-generation IMiDs addresses higher-risk biology in current protocols. |
| Combination depth | Addition of daratumumab to bortezomib-based regimens (Dara-VMP, Dara-VRd) has demonstrated deeper responses and improved outcomes in both newly diagnosed and relapsed myeloma in phase III trials. |
| Mantle cell lymphoma activity | Bortezomib has demonstrated activity in mantle cell lymphoma including relapsed and refractory settings and has been incorporated into frontline regimens for transplant-ineligible patients in combination protocols. |
Individual responses vary. These represent published clinical evidence. Discuss your specific disease and expected outcomes with your hemato-oncologist.
Side effects of Bortezomib
Bortezomib has a distinct side effect profile compared to traditional chemotherapy. The most clinically important toxicity is peripheral neuropathy. Most side effects can be managed with dose adjustments, supportive care, or schedule changes.
| Peripheral neuropathy | Tingling, numbness, burning, or pain in hands and feet. Risk is reduced with subcutaneous injection. Managed by dose reduction, schedule change, or stopping treatment if severe. |
| Fatigue | Common. Usually manageable but may be significant during active treatment cycles. |
| Thrombocytopenia (low platelets) | Common. Platelet counts are monitored regularly. Dose delays may be needed if counts fall significantly. |
| Neutropenia (low white cells) | Increases infection risk. CBC monitored throughout treatment. Dose adjustment may be required. |
| Anemia | Reduction in red blood cell count may cause fatigue or breathlessness. Managed with supportive care or treatment modifications. |
| Nausea and vomiting | Common but generally manageable with anti-nausea medication. Take as prescribed by your care team. |
| Diarrhea or constipation | Gastrointestinal effects are common. Constipation is frequent; diarrhea can also occur. Stay hydrated and report severe or persistent episodes. |
| Injection site reactions | Redness, bruising, or discomfort at the injection site. Rotating injection sites reduces this risk. |
| Fever and infection risk | Immunosuppression increases susceptibility to bacterial, viral, and fungal infections. Report any fever promptly. |
| Herpes zoster (shingles) reactivation | Antiviral prophylaxis is recommended throughout treatment and for a defined period afterward to prevent shingles reactivation. |
| Low blood pressure (hypotension) | Can occur, particularly after injection. Stay hydrated and report dizziness or fainting to your care team. |
| Reduced appetite and weight loss | Common during active treatment cycles. Nutritional support and dietitian review can help. |
Contact your doctor immediately if you develop:
- New or worsening numbness, burning pain, or weakness in hands or feet.
- Fever of 38°C or higher — may indicate serious infection requiring urgent assessment.
- Unusual bruising, bleeding, or very low platelet count symptoms.
- Shortness of breath or chest pain — may indicate cardiac or lung toxicity.
- Signs of shingles: painful rash, blistering, or severe localized skin pain.
- Severe diarrhea or inability to stay hydrated due to vomiting.
- Fainting, severe dizziness, or very low blood pressure after injection.
Safety precautions and drug interactions
Tell your oncologist and pharmacist about all medicines, supplements, and herbal products before starting bortezomib. Several interactions can affect drug levels or increase toxicity.
- CYP3A4 inhibitors (e.g. ketoconazole, itraconazole) may increase bortezomib exposure and toxicity risk.
- CYP3A4 inducers (e.g. rifampicin, carbamazepine, St John's Wort) may reduce bortezomib levels and treatment effectiveness.
- Antidiabetic medicines may interact with bortezomib; blood glucose should be monitored carefully in diabetic patients.
- Warfarin and other anticoagulants require close INR monitoring as bortezomib may alter anticoagulant effect.
- Pregnancy: bortezomib must not be used during pregnancy. Effective contraception is required for women of childbearing potential during treatment and for a defined period after the last dose.
- Breastfeeding: breastfeeding should be discontinued during bortezomib treatment.
- Live vaccines should not be given during bortezomib treatment due to immunosuppression.
- Existing peripheral neuropathy (diabetic, hereditary, or from prior treatment) increases the risk of bortezomib-related nerve toxicity. Discuss baseline neuropathy clearly with your oncologist before starting.
Bortezomib combination treatments
Bortezomib is almost always used in combinations rather than alone, because multi-drug regimens produce deeper and more durable responses in both multiple myeloma and mantle cell lymphoma.
| VRd — bortezomib, lenalidomide, dexamethasone | A commonly used triplet for newly diagnosed transplant-eligible and transplant-ineligible multiple myeloma. One of the most evidence-backed frontline myeloma regimens. |
| VMP — bortezomib, melphalan, prednisone | Used in transplant-ineligible newly diagnosed myeloma. A well-established regimen with long-term outcome data. |
| VCd — bortezomib, cyclophosphamide, dexamethasone | Used in frontline myeloma especially when rapid disease control is needed or in resource-limited settings. |
| Dara-VRd or Dara-VMP (daratumumab added) | Addition of daratumumab to bortezomib-based regimens has shown deeper responses and improved outcomes in phase III trials for both newly diagnosed and relapsed myeloma. |
| Bortezomib + dexamethasone (Vd) | Doublet used in relapsed myeloma or when combination intensity needs to be reduced due to tolerance or organ function. |
| Mantle cell lymphoma combination (VR-CAP) | Bortezomib with rituximab, cyclophosphamide, doxorubicin, and prednisone for transplant-ineligible previously untreated mantle cell lymphoma patients, per EMA label. |
| Pre-transplant induction | Bortezomib-containing regimens are used to induce deep responses before autologous stem cell transplant in transplant-eligible newly diagnosed myeloma patients. |
If Bortezomib stops working
Resistance to bortezomib can develop over time. Understanding the mechanism helps guide next treatment choices. Multiple effective options exist after bortezomib failure in multiple myeloma.
| Proteasome subunit mutations | Mutations in the PSMB5 gene (proteasome beta-5 subunit, the target of bortezomib) can reduce bortezomib binding and effectiveness. This is a direct resistance mechanism. |
| Upregulation of protein-handling pathways | Cancer cells may activate alternative protein degradation pathways, such as autophagy, to compensate for proteasome inhibition and reduce drug dependence. |
| Bone marrow microenvironment protection | Adhesion of myeloma cells to bone marrow stromal cells can confer cell adhesion-mediated drug resistance, reducing sensitivity to proteasome inhibition. |
| Switch to second-generation proteasome inhibitor | Carfilzomib (Kyprolis) and ixazomib (Ninlaro) are next-generation proteasome inhibitors with distinct binding profiles that may retain activity after bortezomib failure. |
| Daratumumab-based next-line regimens | Anti-CD38 monoclonal antibodies such as daratumumab or isatuximab in combination with pomalidomide or carfilzomib are established options after bortezomib failure. |
| Bispecific antibodies and CAR-T therapy | BCMA-targeting bispecific antibodies and CAR-T therapies (e.g. idecabtagene vicleucel, ciltacabtagene autoleucel) are approved or in late-stage trials for heavily pretreated myeloma after multiple prior lines. |
| Clinical trial access | CancerFax can help identify clinical trial options in India, China, and internationally for patients whose myeloma has progressed after bortezomib-based regimens. |
Cost of Bortezomib by country
Generic bortezomib has significantly reduced treatment costs compared with branded Velcade in many markets. However, total treatment cost still depends on the combination regimen, number of cycles, and monitoring required.
| India | Generic bortezomib is manufactured by multiple Indian pharmaceutical companies and is available at significantly lower cost than branded Velcade. Hospital-specific pricing varies. Patient assistance programs may further reduce out-of-pocket costs in some settings. |
| USA | Branded Velcade carries a high list price. Generic bortezomib is available in the US market. Patient assistance programs and insurance coverage are the primary access pathways. Actual cost depends heavily on insurance plan and financial assistance eligibility. |
| UK / Europe | Bortezomib is available through national health systems in the UK and most EU countries for approved indications. NHS covers bortezomib in multiple myeloma under specific criteria. Self-pay costs vary by country and formulation. |
| China | Bortezomib is available in China and is used in approved myeloma treatment protocols. Isatuximab combined with bortezomib and lenalidomide was approved by NMPA for newly diagnosed multiple myeloma. Generic and branded access depends on hospital formulary. |
| Southeast Asia and MENA | Availability varies by country and center. Generic bortezomib is accessible in several markets. CancerFax can help patients identify practical access options in their specific country and hospital setting. |
Availability of Bortezomib globally
Bortezomib is widely available globally. Generic formulations are approved and used in many countries, making it accessible in a broader range of oncology settings than was possible with branded Velcade alone.
India
Generic bortezomib is manufactured by multiple Indian companies and available at major oncology hospitals and specialist hematology centers. It is used routinely in myeloma treatment across public and private hospitals.
China
Bortezomib is approved and used in Chinese oncology centers. NMPA approved combination regimens including bortezomib with newer agents such as isatuximab for newly diagnosed myeloma. Available at leading cancer hospitals.
USA
Generic bortezomib is FDA-approved and available through hospital pharmacies and specialty distributors. Branded Velcade remains available. Patient assistance programs exist for those without adequate insurance coverage.
UK / Europe
EMA-approved for multiple myeloma and mantle cell lymphoma. Available through NHS in the UK and national health systems across EU member states for approved indications.
Southeast Asia
Available in oncology hospitals in Thailand, Singapore, Malaysia, Philippines, and Vietnam. Access depends on center type and formulary. CancerFax can assist with hospital identification and access coordination.
Bortezomib in current clinical trials
Bortezomib continues to be studied as a backbone drug in combination trials, particularly in multiple myeloma. Research focuses on deeper responses, new combination partners, and optimal sequencing strategies.
| Quadruplet induction regimens | Trials evaluating four-drug induction regimens (daratumumab plus bortezomib, lenalidomide, and dexamethasone) for transplant-eligible newly diagnosed myeloma, including maintenance sequencing strategies. |
| Bortezomib in high-risk cytogenetics | Studies examining bortezomib combinations specifically in myeloma with high-risk cytogenetic features such as del(17p), t(4;14), and t(14;16) to improve outcomes in this harder-to-treat subgroup. |
| CAR-T and bispecific combinations | Exploratory and phase II trials examining bortezomib as a bridging or conditioning component in CAR-T and bispecific antibody treatment strategies for relapsed myeloma. |
| Mantle cell lymphoma frontline studies | Trials studying bortezomib-containing induction for older or transplant-ineligible mantle cell lymphoma patients, exploring optimal regimen intensity and maintenance. |
| Minimal residual disease endpoints | Trials using MRD negativity as a primary endpoint to assess depth of response in bortezomib-based regimens, with implications for treatment duration decisions. |
Your treatment journey with Bortezomib
Diagnosis and baseline testing
Pre-treatment assessment
First oncology consultation and treatment planning
Starting bortezomib injections
Ongoing monitoring during cycles
Response assessment
Post-induction decision point
If disease progresses
Questions to ask your oncologist about Bortezomib
- Is bortezomib appropriate for my specific cancer type, stage, and history?
- What combination will I receive and why?
- Will I receive injections under the skin or through a vein?
- How will neuropathy be monitored and what happens if I develop it?
- Do I need antiviral medicine and how long should I take it?
- How will we know if the treatment is working?
- What is the total expected cost and is generic bortezomib an option?
- What are my options if bortezomib stops working?
How CancerFax supports Bortezomib patients
CancerFax helps patients and families navigate access to bortezomib treatment and connects them with specialist hemato-oncologists experienced in multiple myeloma and blood cancer care.
| Report review | Upload your bone marrow biopsy, FISH cytogenetics, serum protein electrophoresis, free light chain results, or CBC reports — our team will review and explain the implications for bortezomib eligibility and regimen planning. |
| Specialist connection | We connect patients with hemato-oncologists specialising in multiple myeloma and mantle cell lymphoma in India, China, and internationally for in-person or remote second opinions. |
| Second opinion for relapsed myeloma | If bortezomib is not working or your myeloma has progressed, CancerFax arranges specialist second opinions to explore next-line options, clinical trials, and advanced therapies. |
| CAR-T and advanced therapy access | CancerFax navigates access to BCMA-targeting CAR-T therapy, bispecific antibodies, and other advanced blood cancer treatments in India, China, and other international centers. |
| Cost and access guidance | We help patients identify generic bortezomib access options, understand treatment costs across countries, and navigate insurance, patient assistance, or hospital cost structures. |
| Clinical trial matching | For patients with relapsed or refractory myeloma, CancerFax identifies relevant clinical trials in India, China, Southeast Asia, and internationally that may offer access to newer combination regimens. |
Frequently asked questions about Bortezomib
Common questions from patients and caregivers about Bortezomib (Velcade)
Bortezomib is a targeted cancer medicine called a proteasome inhibitor. Unlike traditional chemotherapy, which attacks all rapidly dividing cells, bortezomib blocks a specific protein-disposal system inside cancer cells called the proteasome. Myeloma cells are especially sensitive to this because they produce large amounts of protein and depend heavily on the proteasome to survive. This targeted mechanism generally causes a different side-effect profile compared to standard chemotherapy, though it does carry its own risks including peripheral neuropathy and blood count suppression.
Response to bortezomib is typically assessed after each treatment cycle, with meaningful responses often seen within the first two to four cycles in multiple myeloma. Your oncologist will monitor M-protein levels, serum free light chains, or urine protein levels to track response. The exact timeline depends on your disease stage, the combination regimen you are receiving, and individual factors. Ask your doctor when your first formal response assessment is planned.
Peripheral neuropathy is tingling, numbness, burning, or pain in the hands or feet caused by nerve damage. It is one of the most important side effects of bortezomib and can affect quality of life significantly if not managed. Using subcutaneous injection instead of intravenous infusion reduces the risk of neuropathy. Your doctor may reduce the dose, change the schedule, or stop bortezomib if neuropathy becomes severe. Report any new numbness, pain, or difficulty with fine movements promptly — early intervention often prevents worsening.
Yes, generic bortezomib is available in many countries including India, and is used in oncology hospitals worldwide. Generics contain the same active molecule at the same dose and are considered therapeutically equivalent to the branded Velcade. Using the subcutaneous route with generic bortezomib follows the same clinical principles as branded formulations. Discuss with your oncologist or hospital pharmacist about which formulation is available at your treatment center.
Bortezomib suppresses the immune system, which can reactivate dormant herpes zoster virus (the virus that causes shingles). Most oncologists prescribe antiviral prophylaxis with drugs such as acyclovir or valacyclovir for the duration of bortezomib treatment and for a period afterward to prevent shingles reactivation. This is a standard precaution and does not mean you currently have an infection. Ask your doctor if antiviral prevention has been prescribed for you.
If myeloma progresses on a bortezomib-based regimen, your oncologist will reassess the disease with blood tests, bone marrow biopsy if needed, and imaging. Next options may include switching to another proteasome inhibitor such as carfilzomib or ixazomib, adding or changing immunomodulatory drugs, using daratumumab or other monoclonal antibodies, or considering bispecific antibodies, CAR-T therapy, or clinical trials. Multiple myeloma now has many treatment lines available. CancerFax can help you explore second opinion and clinical trial options.
Bortezomib can actually be used in myeloma patients with kidney impairment, including those on dialysis, as it is primarily metabolised by the liver and does not require dose adjustment for kidney function alone. In fact, bortezomib-based regimens are often preferred in myeloma patients with kidney involvement because they can help reverse kidney damage by rapidly reducing the light chain burden causing the problem. Your oncologist will assess all your organ function tests and adjust the plan accordingly.
Bortezomib should not be used during pregnancy. It may cause harm to a developing baby based on its mechanism of action. Women of childbearing potential should use effective contraception during treatment and for a period after the last dose as directed by their oncologist. If you are pregnant, planning to become pregnant, or breastfeeding, discuss this clearly with your doctor before treatment begins. Men on bortezomib should also discuss contraception guidance with their oncologist.